Alphamab Oncology (HKG:9966)
Hong Kong · Delayed Price · Currency is HKD 8.35
+0.21 (2.58%)
Aug 20, 2026, 4:09 PM HKT
Alphamab Oncology Market Cap
Alphamab Oncology has a market cap or net worth of 8.08 billion as of August 20, 2026. Its market cap has decreased by -11.66% in one year.
Market Cap
8.08B
Enterprise Value
6.72B
Revenue
630.11M
Ranking
n/a
PE Ratio
n/a
Stock Price
8.35
ChartMarket Cap Chart
Since December 12, 2019, Alphamab Oncology's market cap has decreased from 12.11B to 8.08B, a decrease of -33.26%. That is a compound annual growth rate of -5.86%.
| Date | Market Cap | % Change |
|---|---|---|
| Aug 20, 2026 | 8.08B | -14.85% |
| Dec 31, 2025 | 9.49B | 181.80% |
| Dec 31, 2024 | 3.37B | -47.42% |
| Dec 29, 2023 | 6.41B | -36.87% |
| Dec 30, 2022 | 10.15B | -20.36% |
| Dec 31, 2021 | 12.74B | -16.28% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 12, 2019 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Ascletis Pharma | 10.38B |
| Shaanxi Micot Pharmaceutical Technology | 10.15B |
| TenNor Therapeutics (Suzhou) | 9.31B |
| CARsgen Therapeutics Holdings | 8.86B |
| Everest Medicines | 8.36B |
| Suzhou Ribo Life Science | 8.36B |
| CStone Pharmaceuticals | 8.18B |
| LongBio Pharma (Suzhou) | 7.81B |